<DOC>
	<DOCNO>NCT01897909</DOCNO>
	<brief_summary>The main objective study investigate impact H. pylorus infection immune activation clinical outcome HIV patient . Other specific study objective : 1 . To investigate effect H. pylori infection immune activation T-cell profile HIV positive patient compare HIV negative control . 2 . To assess influence H. pylorus infection virological immune parameter , clinical progression HIV infection ( WHO stage , opportunistic infection ) . 3 . To assess prevalence H. pylori infection among HIV patient Komfo Anokye Teaching Hospital . 4 . To assess prevalence gastrointestinal symptom HIV patient Kumasi . 5 . To assess association H. pylorus infection gastrointestinal symptom pathology HIV patient . 6 . To compare clinical immunological response antiretroviral therapy HIV-patients without concomitant H. pylorus infection .</brief_summary>
	<brief_title>The Impact Helicobacter Pylori Infection Immune Regulation Clinical Course HIV Patients Ghana</brief_title>
	<detailed_description>Study design : Observational case control study longitudinal follow Recruitment : 1000 HIV patient regularly attend KATH HIV clinic screen H. pylori infection parasitic gastrointestinal infection ( possible confounders ) . Demographic , clinical immunological data patient document study physician . Two group 100 patient H. pylori infection 100 patient without H. pylorus infection select , match accord sex , age , baseline HIV viral load , CD4 cell count confounders . 100 healthy blood donor without HIV infection equally screen H. pylorus gastrointestinal infection serve control group . Study procedure : Baseline : Eligible patient recruit study procedure potential risk associate participate study explain write informed consent obtain . The inclusion study shall way affect decision initiate HAART choice antiretroviral drug . Patients may withdraw consent participate part full time study without give reason . The withdrawal consent way negatively affect management . Recruitment begin ethical approval obtain appropriate authority . Baseline demographic , clinical socioeconomic data , well medical history document attend physician involve HIV service , blind immunological parameter ( except CD4 cell count ) stool test result . Routine laboratory parameter extract patient 's folder , include CD4 cell count , full blood count well liver kidney function test . Stool sample : Patients ask provide fresh stool sample test worm egg , protozoa H. pylorus . After concentration preparation sodium acetate-acetic acid-formalin ( SAF ) , specimen stain iodine kinyoun solution microscopy . Untreated fresh stool frozen -80°C H. pylorus test use commercially available H. pylorus stool antigen test ( Premier Platinum HpSA Plus , Meridian ) accord specification manufacturer . Blood sample : A venous blood sample ( 2x 8ml CPT tube , Becton Dickinson ) take together blood collection routine laboratory investigation . Plasma separate analysis cytokine Elisa cytometric bead array ( CBA ) remain plasma store -80°C . Peripheral blood mononuclear cell ( PBMC ) isolate accord manufacturer 's specification prepare test flow cytometry . A proportion PBMC store liquid nitrogen later analysis . Plasma sample mainly used ass cytokine profile ( inflammatory TH1/TH2 cytokine ) ELISA multi-bead flow array . PBMC analyse flow cytometry determine frequency phenotype Treg , define CD4+ , CD25+ , FoxP3+ cell , activation status T-cell profile ( e.g . CD3 , CD4 , CD8 , CD45RA , CD38 , CD39 , CD69 ) , well apoptosis marker . Ex vivo intracellular cytokine assay IL-2 , IL-4 , IL-10 IL-17 perform unstimulated stimulated PBMC . FACS analyse conduct KATH immunology laboratory , use FACSCalibur flow cytometer ( Becton Dickinson ) CellQuest Pro software . Follow-up : After baseline evaluation , patient follow one year . 12 month baseline evaluation , venous blood sample ( 2x8ml CPT ) take immunological parameter repeat specified baseline evaluation . Patients receive treatment intestinal pathogen , start antiretroviral therapy , accord clinical indication , ask provide additional blood sample immunological evaluation three month initiation treatment . In case treatment intestinal pathogen , stool sample also collect three month confirm eradication . End point : Primary end point : 1 . Frequency activation status T-cell subset HIV positive patient versus without H. pylorus infection 2 . Change CD4 cell HIV viral load HIV positive patient versus without H. pylori infection follow-up 3 . Incidence clinical event HIV positive patient versus without H. pylori infection follow-up Secondary end point : 1 . Prevalence H. pylorus infection HIV patient Kumasi , Ghana , compare blood donor 2 . Prevalence infection helminth gastrointestinal parasite HIV patient Kumasi , Ghana , compare blood donor 3 . Prevalence risk factor gastrointestinal infection HIV patient Kumasi , Ghana 4 . Association gastrointestinal infection gastrointestinal symptom 5 . Association gastrointestinal infection nutrition status , waste anemia HIV patient Kumasi , Ghana Treatment regimens : The management HIV infection carry accord national institutional guideline influence study participation . Patients find infected pathogen parasite ( e. g. Ascaris lumbricoides ) offer treatment . Patients H. pylori infection pertinent symptom offer eradication therapy accord national guideline . If treatment cost cover National Health Insurance Scheme ( NHIS ) , cost cover study budget . Interventions : No intervention carry within study . Sample size calculation : Calculations plan sample size do quote since well substantiate . Since exist data alteration T-cell population H. pylorus infection , substantiate sample-size analysis possible . We assume difference frequency regulatory T cell ( Treg ) , one key end point , range 1-2 % , minimum clinically significant . To demonstrate significant difference 1 % group statistical power 0.9 α=0.05 , use unpaired , 2-sided t-test , sample size 380 patient would need . No reliable data exist prevalence H. pylori infection among HIV patient Ghana . According data African country , assume prevalence 60-80 % . To sure obtain sufficient H. pylorus negative patient able select match group H. pylori uninfected patient , still suggest screen 1000 HIV infect patient . All patient recruit screen H. pylorus analyse clinical progression HIV disease . Likewise , exist data estimate consequence clinical course . However , difference difficult identify due high variability clinical course HIV disease , multiplicity confounders . Statistical analysis : Continuous variable compare paired Student 's t-tests Wilcoxon sign rank test depend statistical distribution . Linear regression analysis Fisher 's transformation test use continuous variable . Proportions compare chi-square test . Multiple regression analysis logistic regression analysis perform appropriate order correct confounders . A p-value &lt; 0.05 consider statistically significant .</detailed_description>
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>Bacterial Infections</mesh_term>
	<mesh_term>Helicobacter Infections</mesh_term>
	<criteria>able willing give inform write consent age &gt; 18 year CD4 cell &gt; 350/µl willing able comply study procedure HIV2 HIV1/2 coinfection Active opportunistic infection acute systemic infection ( e. g. pneumonia ) malignancy ( e. g. lymphoma ) Antihelminth anti helicobacter pylorus treatment past 6 month Anemia ( Haemoglobin &lt; 7 g/dl ) Active systemic opportunistic infection tumor ( e. g. pneumonia , tuberculosis ) Patient highly active antiretroviral therapy ( HAART ) HAART 3 month prior recruitment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>